Mission Wealth Management LP bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,155 shares of the medical instruments supplier's stock, valued at approximately $262,000.
Several other institutional investors and hedge funds also recently made changes to their positions in BDX. Bank of Jackson Hole Trust purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at $25,000. Sierra Ocean LLC purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at $29,000. Ashton Thomas Securities LLC purchased a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $33,000. Tompkins Financial Corp boosted its position in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 46 shares during the period. Finally, Kennebec Savings Bank purchased a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $46,000. Institutional investors own 86.97% of the company's stock.
In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of the firm's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now directly owns 16,201 shares in the company, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the firm's stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the sale, the executive vice president now owns 6,141 shares of the company's stock, valued at approximately $1,371,469.53. This represents a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,061 shares of company stock worth $1,379,521. 0.36% of the stock is owned by corporate insiders.
Several equities research analysts have recently commented on BDX shares. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 28th. StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday. Finally, Barclays raised their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $278.29.
Get Our Latest Analysis on Becton, Dickinson and Company
Shares of NYSE BDX opened at $225.19 on Friday. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The stock has a market cap of $64.66 billion, a P/E ratio of 37.41, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. The firm has a 50-day moving average of $232.96 and a 200 day moving average of $232.78. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's leadership believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 69.10%.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.